BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

660 related articles for article (PubMed ID: 24926520)

  • 1. Bleeding associated with uterine leiomyomas. Tailor treatment to the individual patient.
    Prescrire Int; 2014 May; 23(149):130-5. PubMed ID: 24926520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The management of uterine leiomyomas.
    Vilos GA; Allaire C; Laberge PY; Leyland N;
    J Obstet Gynaecol Can; 2015 Feb; 37(2):157-178. PubMed ID: 25767949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic management of uterine fibroid tumors: updated French guidelines.
    Marret H; Fritel X; Ouldamer L; Bendifallah S; Brun JL; De Jesus I; Derrien J; Giraudet G; Kahn V; Koskas M; Legendre G; Lucot JP; Niro J; Panel P; Pelage JP; Fernandez H;
    Eur J Obstet Gynecol Reprod Biol; 2012 Dec; 165(2):156-64. PubMed ID: 22939241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas.
    Magalhães J; Aldrighi JM; de Lima GR
    Contraception; 2007 Mar; 75(3):193-8. PubMed ID: 17303488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The management of uterine leiomyomas.
    Lefebvre G; Vilos G; Allaire C; Jeffrey J; Arneja J; Birch C; Fortier M; Wagner MS;
    J Obstet Gynaecol Can; 2003 May; 25(5):396-418; quiz 419-22. PubMed ID: 12738981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EMAS position statement: management of uterine fibroids.
    Pérez-López FR; Ornat L; Ceausu I; Depypere H; Erel CT; Lambrinoudaki I; Schenck-Gustafsson K; Simoncini T; Tremollieres F; Rees M;
    Maturitas; 2014 Sep; 79(1):106-16. PubMed ID: 24975954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uterine artery embolization as a treatment option for uterine myomas.
    Marshburn PB; Matthews ML; Hurst BS
    Obstet Gynecol Clin North Am; 2006 Mar; 33(1):125-44. PubMed ID: 16504811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of menorrhagia with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
    Wildemeersch D; Schacht E
    Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):93-101. PubMed ID: 11518454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological findings associated with the presence of a mirena intrauterine system at hysterectomy.
    Rizkalla HF; Higgins M; Kelehan P; O'Herlihy C
    Int J Gynecol Pathol; 2008 Jan; 27(1):74-8. PubMed ID: 18156979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormal uterine bleeding: managing endometrial dysfunction and leiomyomas.
    Brennan A; Hickey M
    Med J Aust; 2018 Feb; 208(2):90-95. PubMed ID: 29385977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of the levonorgestrel-releasing intrauterine system in uterine leiomyoma.
    Kriplani A; Awasthi D; Kulshrestha V; Agarwal N
    Int J Gynaecol Obstet; 2012 Jan; 116(1):35-8. PubMed ID: 21959070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrauterine devices: an effective alternative to oral hormonal contraception.
    Prescrire Int; 2009 Jun; 18(101):125-30. PubMed ID: 19637436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The medical management of abnormal uterine bleeding in reproductive-aged women.
    Bradley LD; Gueye NA
    Am J Obstet Gynecol; 2016 Jan; 214(1):31-44. PubMed ID: 26254516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ulipristal acetate versus placebo for fibroid treatment before surgery.
    Donnez J; Tatarchuk TF; Bouchard P; Puscasiu L; Zakharenko NF; Ivanova T; Ugocsai G; Mara M; Jilla MP; Bestel E; Terrill P; Osterloh I; Loumaye E;
    N Engl J Med; 2012 Feb; 366(5):409-20. PubMed ID: 22296075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial.
    Muneyyirci-Delale O; Richard-Davis G; Morris T; Armstrong J
    Clin Ther; 2007 Aug; 29(8):1682-91. PubMed ID: 17919549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guideline No. 389-Medical Management of Symptomatic Uterine Leiomyomas - An Addendum.
    Laberge PY; Murji A; Vilos GA; Allaire C; Leyland N; Singh SS
    J Obstet Gynaecol Can; 2019 Oct; 41(10):1521-1524. PubMed ID: 31548041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial.
    Osuga Y; Enya K; Kudou K; Tanimoto M; Hoshiai H
    Obstet Gynecol; 2019 Mar; 133(3):423-433. PubMed ID: 30741797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lessons learned from the preclinical drug discovery of asoprisnil and ulipristal for non-surgical treatment of uterine leiomyomas.
    Maruo T; Ohara N; Yoshida S; Nakabayashi K; Sasaki H; Xu Q; Matsuo H; Sitruk-Ware R; Yamada H
    Expert Opin Drug Discov; 2011 Sep; 6(9):897-911. PubMed ID: 22646213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Management of menometrorrhagia in women with and without pregnancy intention: hierarchy of therapies].
    Roman H; Loisel C; Puscasiu L; Sentilhes L; Marpeau L
    J Gynecol Obstet Biol Reprod (Paris); 2008 Dec; 37 Suppl 8():S405-17. PubMed ID: 19268219
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 33.